Phase II Evaluation of Adjuvant Hyperfractionated Radiation and Docetaxel for HPV Associated Oropharynx Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Docetaxel (Primary)
- Indications Oropharyngeal cancer
- Focus Therapeutic Use
- 14 Nov 2017 Planned End Date changed from 1 Oct 2017 to 1 Oct 2018.
- 14 Nov 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2018.
- 14 Nov 2017 Status changed from suspended to active, no longer recruiting.